Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew D Hellmann

Showing results (101-110 of 172) with videos related to

Pageof 18
Sort By:
The Journal of Experimental Medicine|December 22, 2021
TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasionMojdeh Shakiba, Paul Zumbo, Gabriel Espinosa-Carrasco, et al.
The Journal of Experimental Medicine|May 23, 2022
Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functionsSara E Schad, Andrew Chow, Levi Mangarin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 26, 2020
The Genomic Landscape of <i>SMARCA4</i> Alterations and Associations with Outcomes in Patients with Lung CancerAdam J Schoenfeld, Chai Bandlamudi, Jessica A Lavery, et al.
Journal for Immunotherapy of Cancer|May 31, 2022
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesotheliomaRamaswamy Govindan, Charu Aggarwal, Scott J Antonia, et al.
JCO Precision Oncology|December 14, 2019
Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung CancerNatalie I Vokes, David Liu, Biagio Ricciuti, et al.
Journal for Immunotherapy of Cancer|July 18, 2018
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)Julie R Brahmer, Ramaswamy Govindan, Robert A Anders, et al.
The New England Journal of Medicine|April 17, 2018
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational BurdenMatthew D Hellmann, Tudor-Eliade Ciuleanu, Adam Pluzanski, et al.
Nature Cancer|August 29, 2022
Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancerRami S Vanguri, Jia Luo, Andrew T Aukerman, et al.
Science (New York, N.Y.)|March 14, 2015
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancerNaiyer A Rizvi, Matthew D Hellmann, Alexandra Snyder, et al.
British Journal of Cancer|December 29, 2021
Immune biomarkers and response to checkpoint inhibition of BRAF<sup>V600</sup> and BRAF non-V600 altered lung cancersYonina R Murciano-Goroff, Terry Pak, Sebastian Mondaca, et al.
Pageof 18

Showing results (101-110 of 172) with videos related to

Sort By:
Pageof 18
The Journal of Experimental Medicine|December 22, 2021
TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasionMojdeh Shakiba, Paul Zumbo, Gabriel Espinosa-Carrasco, et al.
The Journal of Experimental Medicine|May 23, 2022
Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functionsSara E Schad, Andrew Chow, Levi Mangarin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 26, 2020
The Genomic Landscape of <i>SMARCA4</i> Alterations and Associations with Outcomes in Patients with Lung CancerAdam J Schoenfeld, Chai Bandlamudi, Jessica A Lavery, et al.
Journal for Immunotherapy of Cancer|May 31, 2022
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesotheliomaRamaswamy Govindan, Charu Aggarwal, Scott J Antonia, et al.
JCO Precision Oncology|December 14, 2019
Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung CancerNatalie I Vokes, David Liu, Biagio Ricciuti, et al.
Journal for Immunotherapy of Cancer|July 18, 2018
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)Julie R Brahmer, Ramaswamy Govindan, Robert A Anders, et al.
The New England Journal of Medicine|April 17, 2018
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational BurdenMatthew D Hellmann, Tudor-Eliade Ciuleanu, Adam Pluzanski, et al.
Nature Cancer|August 29, 2022
Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancerRami S Vanguri, Jia Luo, Andrew T Aukerman, et al.
Science (New York, N.Y.)|March 14, 2015
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancerNaiyer A Rizvi, Matthew D Hellmann, Alexandra Snyder, et al.
British Journal of Cancer|December 29, 2021
Immune biomarkers and response to checkpoint inhibition of BRAF<sup>V600</sup> and BRAF non-V600 altered lung cancersYonina R Murciano-Goroff, Terry Pak, Sebastian Mondaca, et al.
Pageof 18